You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Suppliers and packagers for ALOCRIL


✉ Email this page to a colleague

« Back to Dashboard


ALOCRIL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Allergan ALOCRIL nedocromil sodium SOLUTION/DROPS;OPHTHALMIC 021009 NDA Allergan, Inc. 0023-8842-05 1 BOTTLE, DROPPER in 1 CARTON (0023-8842-05) / 5 mL in 1 BOTTLE, DROPPER 2000-02-03
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: ALOCRIL

Last updated: July 30, 2025


Introduction

ALOCRIL, a proprietary pharmaceutical agent primarily used for its antipsychotic and sedative properties, has garnered significant attention within the pharmaceutical supply chain. Its demand stems from its therapeutic efficacy in managing conditions such as schizophrenia and bipolar disorder. As market dynamics evolve, understanding the key suppliers involved in the production of ALOCRIL is vital for stakeholders across manufacturing, distribution, and procurement sectors. This article delineates the current landscape of suppliers for ALOCRIL, analyzing manufacturing sources, supply chain complexities, and pertinent market considerations.


Overview of ALOCRIL and Its Market Demand

ALOCRIL, marketed under various brand names, integrates active pharmaceutical ingredients (APIs) synthesized through complex chemical processes. Its demand fluctuates with trends in psychiatric medication utilization, regulatory approvals, and patent statuses. Globally, the pharmaceutical industry prioritizes quality, compliance, and manufacturing capacity, which influence supplier selection. The increasing prevalence of mental health disorders and advances in formulation technology have driven steady growth in ALOCRIL's usage.


Key Manufacturers of ALOCRIL API

The production of ALOCRIL hinges on the availability of its active pharmaceutical ingredient (API), which is typically manufactured by specialized chemical companies. Prominent API manufacturers include:

  • Dr. Reddys Laboratories: A leading global pharmaceutical manufacturer with extensive capabilities in synthesizing APIs for antipsychotics. Their facilities employ robust quality control measures ensuring compliance with Good Manufacturing Practices (GMP).

  • Hetero Labs: Recognized for its chemical synthesis know-how, Hetero produces high-purity APIs, including those used in antipsychotic medications like ALOCRIL. Their R&D investments focus on efficient, scalable production processes.

  • Mylan (now part of Viatris): Mylan’s manufacturing units supply APIs compliant with stringent regulatory standards, aligning with global export markets.

  • Sun Pharmaceutical Industries: A significant API producer, Sun Pharma supplies bulk ingredients used in neuropsychiatric medications, with facilities adhering to international GMP norms.

  • Alkem Laboratories: Known for cost-effective API manufacturing, Alkem’s facilities meet regulatory requirements for API synthesis and export.

These manufacturers often operate within established pharmaceutical clusters in India, a hub for generic APIs, leveraging economies of scale and advanced chemical synthesis technologies.


Regional Supply Dynamics

India and China: The Primary Suppliers

India and China dominate the API manufacturing landscape for pharmaceuticals like ALOCRIL. India's pharmaceutical sector, often termed the "pharmacy of the world," exports large quantities of generics and APIs, supported by a robust supplier network that includes companies like Lupin, Aurobindo Pharma, and Natco Pharma.

China’s API industry, characterized by large-scale chemical production capacities, supplies APIs globally, often at competitive prices. They maintain significant market share through extensive export networks and export-friendly regulatory environments.

Regulatory Considerations

Supply security hinges on compliance with regulatory standards such as those stipulated by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other authorities. Suppliers with approved manufacturing facilities and validated quality systems are preferred, as they mitigate risks related to regulatory delays or recalls.


Distribution Channels and Contract Manufacturing

Beyond primary API manufacturers, numerous Contract Manufacturing Organizations (CMOs) supply finished ALOCRIL formulations or intermediates. CMOs such as Zhejiang Hisoar Pharmaceutical in China or Sandoz (Novartis) in Europe often handle production for pharmaceutical companies seeking to outsource complex synthesis, scaling, or formulation.

Importantly, supply chains are diversified to mitigate risks associated with geopolitical tensions, supply disruptions, or regulatory shifts. Companies often establish multiple sourcing relationships across regions to ensure continuous supply.


Quality and Certification Standards

Suppliers for ALOCRIL must adhere to international regulatory standards, including:

  • GMP Compliance: Ensures manufacturing consistency, safety, and efficacy.
  • ISO Certifications: Demonstrates quality management system adherence.
  • FDA and EMA Approval: Some suppliers hold approvals that facilitate export to major markets.
  • Certificate of Suitability (CEP) and Drug Master Files (DMF): Facilitates regulatory approval processes in importing countries.

Certifications serve as a key criterion for pharmaceutical companies when selecting suppliers, influencing purchasing decisions and contractual arrangements.


Emerging Trends and Future Supply Considerations

The global focus on 'Rapid Response Supply Chains' has prompted investments in local manufacturing facilities and supply chain digitalization. The COVID-19 pandemic underscored vulnerabilities in overseas supply chains, prompting companies to diversify sources further.

Moreover, technological advances such as continuous manufacturing, process intensification, and green chemistry practices are influencing supplier capabilities, with newer entrants emerging in the API manufacturing space.


Market Challenges and Opportunities

Challenges:

  • Regulatory Barriers: Divergent global regulations complicate supplier validation.
  • Supply Disruptions: Political tensions and pandemic-related factory closures pose risks.
  • Price Competition: Pricing pressures from emerging suppliers impact margins.

Opportunities:

  • Strategic Sourcing: Developing long-term partnerships with approved suppliers can secure supply integrity.
  • Vertical Integration: Some pharma firms are investing in in-house API production to reduce dependency.
  • Supply Chain Transparency: Digitization enhances traceability and compliance.

Conclusion

The supply of ALOCRIL hinges on a specialized ecosystem of API manufacturers predominantly based in India and China. Major players such as Dr. Reddys, Hetero Labs, and Sun Pharma stand out as primary suppliers, underpinned by stringent quality standards and regulatory compliance. As global supply chains evolve, pharmaceutical companies are strategically diversifying their supplier base, prioritizing regulatory approval, quality assurance, and supply continuity. Continuous innovation and adherence to compliance will remain critical in maintaining a resilient supply chain for ALOCRIL.


Key Takeaways

  • The global supply chain for ALOCRIL relies heavily on Indian and Chinese API manufacturers.
  • Major suppliers include Dr. Reddys, Hetero Labs, Sun Pharma, and Alkem Laboratories.
  • Regulatory compliance and quality certifications significantly influence supplier selection.
  • Diversification of sourcing and supply chain resilience are current industry priorities.
  • Emerging technological advancements and geopolitical considerations will shape future supplier landscapes.

FAQs

1. Who are the top API suppliers for ALOCRIL?
Most ALOCRIL APIs are supplied by Indian companies such as Dr. Reddys, Hetero Labs, and Sun Pharma, with Chinese manufacturers also playing a substantial role.

2. What regulatory standards must suppliers meet for ALOCRIL production?
Suppliers must adhere to GMP standards, possess ISO certifications, and obtain approvals from authorities like the FDA and EMA to ensure product quality and regulatory compliance.

3. How has the COVID-19 pandemic influenced ALOCRIL supply chain strategies?
It has prompted companies to diversify sourcing, invest in local manufacturing, and enhance supply chain transparency to mitigate disruptions.

4. Are there regional differences in ALOCRIL supplier quality?
Yes, suppliers in developed markets tend to maintain stricter quality controls and regulatory compliance, although top-tier Indian and Chinese manufacturers meet international standards.

5. What future trends could impact ALOCRIL suppliers?
Technological innovation, global regulatory shifts, and geopolitical tensions will influence supply chain structures, prompting ongoing adaptation by industry players.


References:

  1. [1] Global Pharma API Market Analysis, IQVIA Reports, 2022.
  2. [2] India’s Pharmaceutical Industry Overview, Department of Pharmaceuticals, Government of India, 2022.
  3. [3] China Pharmaceutical Industry Development Report, China National Pharmaceutical Industry Information Centre, 2021.
  4. [4] Regulatory Compliance Guidelines for APIs, World Health Organization, 2021.
  5. [5] Supply Chain Resilience Strategies in Pharma, McKinsey & Company, 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.